Wantstats
Company ProfilePremium

EKF Diagnostics

Company Profile Analysis

Book DemoRegister Your Interest
ESOMAR 23 Corporate BadgeISO Certifications Badge
EKF Diagnostics - Healthcare showcase

Year Founded & Workforce

1990

300 Employees

Industry

Healthcare

Services

Biomarker Test
E

EKF Diagnostics Employee Contacts

22 verified contactsNames, job titles, seniority and locations

View Employee Contacts

EKF Diagnostics Overview

Company Headquarters: Penarth, Cardiff, UK

Founded: 1990

Workforce: ~300

Company Working: EKF Diagnostics is a healthcare company. It specializes in the development, manufacture, and distribution of point of care analyzers for hemoglobin, HbA1c, glucose, lactate, as well as a wide range of clinical chemistry products and biomarker-based ELISA and rapid tests. EKF Diagnostics provides its products to more than 100 countries. It is listed on the alternative investment market at the London Stock Exchange

Strategy

EKF Diagnostics aims to develop and market biomarker tests and products and enter new markets that complement or expand its existing business. The company strategizes to diversify its product portfolio through strategic acquisitions. Its focus is to improve the quality of life of patients by providing them with better healthcare facilities and better treatment options.

Company Snapshot

$48.31M

Revenue

300

Employees

1990

Founded

Penarth, Cardiff, UK

Headquarters

SWOT Analysis

Strengths

  • Growing presence in the US
  • Strong product portfolio

Weaknesses

  • Management of cash flow

Opportunities

  • Focus on emerging economies providing growth opportunities
  • Acquisitions could strengthen growth rates and profitability

Threats

  • Growing competition from other companies
  • Stringent political and regulatory environment

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateApproachDevelopment
September 2019ExpansionEKF Diagnostics opened a new research & development facility at its Cardiff, UK headquarters. The new Special Projects Laboratory will focus on developing new applications for the company’s many point-of-care and central laboratory medical products to enable the company to enter new market sectors, as well as providing additional diagnostics sales and regulatory support.
August 2018AgreementEKF Diagnostics signed an agreement with McKesson Medical-Surgical Inc., a partner of the McKesson Corporation. McKesson is the oldest and largest healthcare company in the US, serving more than 50% of the US hospitals and 20% of the physicians. Hence, this agreement will help increase its molecular diagnostic sales in the US and around the world.
May 2017ExpansionThe company expanded the distribution of its procalcitonin liquicolor test into Eastern Europe, the Middle East, and Asia-Pacific. It has started working closely with three major distributors covering the Philippines, Indonesia, and Vietnam, and other countries to introduce procalcitonin (PCT) into hospitals.

Product Offering

  • EKF Diagnostics
    • Biomarker Test

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

By Business Segment: Sales rose from USD 48.3 Mn in 2016 to USD 56.7 Mn in 2018.
EKF Diagnostics — By Business Segment
Series (USD Mn)201620172018
Sales48.35256.7

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.

Get Contacts →